| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170522-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $89.90 | |
| Ab170522-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $447.90 | |
| Ab170522-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,107.90 | |
| Ab170522-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,797.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Otelixizumab (anti-CD3), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CD3D, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Anti-CD3 Reference Antibody (otelixizumab) | Otelixizumab | ChAglyCD3 | TRX 4 | 4930549J05Rik antibody | A430104F18Rik antibody | AW552088 antibody | Cd247 antibody | CD247 antigen antibody | CD247 antigen, zeta subunit antibody | CD247 molecule antibody |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | CD3D |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | BINDING AGENT |
| Mechanism of action | Antibody of CD3e |
| Product Description | Otelixizumab (anti-CD3) is a recombinant monoclonal antibody to CD3. Otelixizumab is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | lambdaC2 |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 181.4 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 881191-44-2 |
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 with Otelixizumab (anti-CD3) (Ab170522) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 (red) with Otelixizumab (anti-CD3) (Ab170522) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Otelixizumab (anti-CD3) (Ab170522) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD3 (red) with Otelixizumab (anti-CD3) (Ab170522). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Otelixizumab (anti-CD3) (Ab170522) - SEC
The purity of Otelixizumab (anti-CD3) (Ab170522) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 235 |
|---|---|
| Wikipedia | Otelixizumab |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001498 | Certificate of Analysis | Nov 02, 2023 | Ab170522 |
| ZJ23F1001497 | Certificate of Analysis | Nov 02, 2023 | Ab170522 |
| 1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al.. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.. N Engl J Med, 352 (25): (2598-608). [PMID:15972866] [10.1021/op500134e] |
| 2. Chatenoud L, Bluestone JA. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity.. Nat Rev Immunol, 7 (8): (622-32). [PMID:17641665] [10.1021/op500134e] |
| 3. Kaufman A, Herold KC. (2009) Anti-CD3 mAbs for treatment of type 1 diabetes.. Diabetes Metab Res Rev, 25 (4): (302-6). [PMID:19319985] [10.1021/op500134e] |
| 4. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, Bode B, Aronoff S, Holland C, Carlin D et al.. (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.. Lancet, 378 (9790): (487-97). [PMID:21719095] [10.1021/op500134e] |
| 5. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.. Eur J Immunol, 23 (2): (403-11). [PMID:8436176] [10.1021/op500134e] |
| 6. de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Le Deist F. (2004) Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.. J Clin Invest, 114 (10): (1512-7). [PMID:15546002] [10.1021/op500134e] |
| 7. Phillips, J H JH and 5 more authors.. (1992) Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins.. The Journal of experimental medicine, (1): [PMID:1372642] |
| 8. Barber, E K EK, Dasgupta, J D JD, Schlossman, S F SF, Trevillyan, J M JM and Rudd, C E CE.. (1989) The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2470098] |
| 9. Alexander, D D and 5 more authors.. (1989) Dephosphorylation of the human T lymphocyte CD3 antigen.. European journal of biochemistry, (15): [PMID:2540970] |
| 10. van den Elsen, P P, Georgopoulos, K K, Shepley, B A BA, Orkin, S S and Terhorst, C C.. (1986) Exon/intron organization of the genes coding for the delta chains of the human and murine T-cell receptor/T3 complex.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2939461] |
| 11. Tunnacliffe, A A, Sims, J E JE and Rabbitts, T H TH.. (1986) T3 delta pre-mRNA is transcribed from a non-TATA promoter and is alternatively spliced in human T cells.. The EMBO journal, [PMID:3488209] |
| 12. van den Elsen, P P and 6 more authors.. (1984) Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex.. Nature, [PMID:6095101] |
| 13. Wilde, M I MI and Goa, K L KL.. (1996) Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.. Drugs, [PMID:8861551] |
| 14. Doucey, Marie-Agnès MA and 7 more authors.. (2003) CD3 delta establishes a functional link between the T cell receptor and CD8.. The Journal of biological chemistry, (31): [PMID:12215456] |
| 15. Salomon, Arthur R AR and 10 more authors.. (2003) Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.. Proceedings of the National Academy of Sciences of the United States of America, (21): [PMID:12522270] |
| 16. Dadi, Harjit K HK, Simon, Amos J AJ and Roifman, Chaim M CM.. (2003) Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency.. The New England journal of medicine, (6): [PMID:14602880] |
| 17. Jin, Pei P and 7 more authors.. (2004) PCR isolation and cloning of novel splice variant mRNAs from known drug target genes.. Genomics, [PMID:15028279] |
| 18. Brill, Laurence M LM and 5 more authors.. (2004) Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.. Analytical chemistry, (15): [PMID:15144186] |
| 19. Arnett, Kelly L KL, Harrison, Stephen C SC and Wiley, Don C DC.. (2004) Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment.. Proceedings of the National Academy of Sciences of the United States of America, (16): [PMID:15534202] |
| 20. Yu, Grace P and 13 more authors.. (2011) Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.. Pediatric transplantation, [PMID:21883749] |
| 21. Zugmaier, Gerhard G, Klinger, Matthias M, Schmidt, Margit M and Subklewe, Marion M.. (2015) Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.. Molecular immunology, [PMID:25883042] |
